NYMXF NYMOX PHARMACEUTICAL CORP IFRS
In Vitro & In Vivo Diagnostic Substances · OTC · SEC CIK 1018735 · Fiscal year ends 12/31
Financial factors as of 2024-12-31 (FY2024), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2024Q4*2024-12-31 | 2024Q32024-09-30 | 2023Q4*2023-12-31 | 2023Q3*2023-09-30 | 2023Q2*2023-06-30 | 2023Q1*2023-03-31 | 2022Q4*2022-12-31 | 2022Q3*2022-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross profit | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| R&D expense | $624,000 | $511,000 | $2.02M | $661,000 | $594,000 | $720,000 | -$2.26M | $892,000 |
| SG&A expense | $164,000 | $142,000 | $2.83M | $353,000 | $505,000 | $665,000 | $590,000 | $586,000 |
| Interest expense | $86,000 | $63,000 | $25,000 | $22,000 | $10,000 | $2,000 | -$44,000 | $10,000 |
| Pretax income | -$857,000 | -$716,000 | -$5.31M | -$1.04M | -$1.11M | -$1.39M | -$1.34M | -$1.49M |
| Net income | -$857,000 | — | -$5.31M | -$6.03M | $3.88M | -$1.39M | -$1.34M | -$1.49M |
| EPS (basic) | — | — | — | — | — | — | — | -0.02 |
| EPS (diluted) | — | — | — | — | — | — | — | -0.02 |
| Balance sheet | ||||||||
| Cash & equivalents | $74,000 | $41,000 | $70,000 | $76,000 | $132,000 | $351,000 | $1.40M | $2.70M |
| Receivables | $0 | — | $0 | — | — | — | $0 | — |
| Inventory | — | — | — | — | — | — | $0 | $34,000 |
| Current assets | $653,000 | $623,000 | $625,000 | $654,000 | $214,000 | $461,000 | $1.46M | $2.91M |
| PP&E, netmay include right-of-use assets (IFRS) | $1,000 | $1,000 | $2,000 | $5,000 | $8,000 | $10,000 | $10,000 | $13,000 |
| Total assets | $654,000 | $624,000 | $627,000 | $669,000 | $271,000 | $575,000 | $1.62M | $3.14M |
| Current liabilities | $7.43M | $6.92M | $3.80M | $2.57M | $3.15M | $2.37M | $2.11M | $2.36M |
| Total liabilities | $7.43M | $6.92M | $3.80M | $2.57M | $3.15M | $2.37M | $2.11M | $2.37M |
| Shareholders' equity | -$6.78M | -$6.30M | -$3.17M | -$1.90M | -$2.88M | -$1.80M | -$482,000 | $773,000 |
| Shares outstanding | 94.54M | 93.54M | 93.54M | 93.27M | 91.27M | 90.52M | 90.52M | 91.27M |
| Cash flow statement | ||||||||
| Operating cash flow | -$717,000 | — | -$897,000 | -$1.26M | -$909,000 | -$988,000 | -$1.25M | -$1.31M |
| Capital expenditure | $0 | — | $0 | $0 | $0 | $3,000 | $0 | $0 |
| Free cash flow | -$717,000 | — | -$897,000 | -$1.26M | -$909,000 | -$991,000 | -$1.25M | -$1.31M |
| Investing cash flow | $0 | — | $0 | $0 | $0 | -$3,000 | $0 | $0 |
| Financing cash flow | $750,000 | — | $891,000 | $1.21M | $690,000 | -$61,000 | -$52,000 | -$60,000 |
| Stock-based compensation | $159,000 | — | $3.24M | $11,000 | $32,000 | $70,000 | $84,000 | $33,000 |
Free plan shows the latest 8 periods; Pro shows all 30 🔒
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.